ZypAdhera ® (olanzapine pamoate monohydrate)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: ZypAdhera Summary of Product Characteristics (SmPC)

ZypAdhera® (Olanzapine pamoate): Use in patients with COVID-19 (Coronavirus disease 2019)

The use of olanzapine long-acting injection in patients with COVID-19 has not been studied.

Detailed Information

Coronavirus disease 2019 (COVID-19) is an infectious respiratory disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), previously referred to as "2019 novel coronavirus."1

Lilly has not studied the use of olanzapine long-acting injection in patients with COVID-19 nor in patients at risk of contracting COVID-19.

Clinicians should use their clinical judgment in determining the most appropriate approach in treating a patient with olanzapine long-acting injection who has confirmed or suspected COVID-19.

Warnings and Precautions

Caution should be exercised in patients with low leukocyte and/or neutrophil counts for any reason, in patients

  • receiving medicines known to cause neutropenia, in patients with

  • with a history of drug-induced bone marrow depression/toxicity, 

  • with bone marrow depression caused by concomitant illness, radiation therapy or chemotherapy and 

  • with hypereosinophilic conditions or with myeloproliferative disease.2

Neutropenia has been reported commonly when olanzapine and valproate are used concomitantly.2

In addition, please note the following common adverse events (≥ 1/100 to < 1/10) that may occur in patients being treated with olanzapine pamoate. The following list includes adverse reactions observed from spontaneous reporting and in clinical trials. For full list of undesirable effects, please refer to section 4.8 of the ZypAdhera Summary of Product Characteristics.

General disorders

  • Asthenia (common)

  • Fatigue (common)

  • Pyrexia (common) (As assessed by measured values from clinical trials in the Olanzapine Integrated Database.)2

Infectious Disease Resources

For the most current information regarding the coronavirus, please refer to the websites of local health authorities and/or the WHO website at WHO Coronavirus disease (COVID-19) outbreak.

References

1. World Health Organization. Naming the coronavirus disease (COVID-19) and the virus that causes it. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it. Accessed March 11, 2020.

2. ZypAdhera [summary of product characteristics] Eli Lilly Netherland B.V., The Netherlands.

Glossary

CDC = The Center for Disease Control

Lilly = Eli Lilly and Company

WHO = World Health Organization

Date of Last Review: March 24, 2020

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Ask us a question Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question